Non-surgical Management;dMMR/MSI-H Gastric Cancer;Neoadjuvant ImmunotherapyNCT07646574
Non-surgical Management After NIT for dMMR/MSI-H GC
An observational study of Non-surgical Management;dMMR/MSI-H Gastric Cancer;Neoadjuvant Immunotherapy, run by Yong Zhou at 1 site in China.
Trial summary
Gastric cancer is one of the most common cancers worldwide and has a poor prognosis Immunotherapy significantly improves the prognosis of gastric cancer. In resectable gastric/gastroesophageal junction adenocarcinoma (GAC/GEJA) C, mismatch repair deficiency (dMMR)/microsatellite instability (MSI-H) can improve… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non-surgical Management;dMMR/MSI-H Gastric Cancer;Neoadjuvant Immunotherapy
- How many people
- 12 participants
- Where
- 1 siteChina
- Study dates
- 1 Jul 2026to 30 Jun 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Patients over 18 years old with advanced dMMR/MSI-H gastric cancer
Who may be able to join
- Patients over 18 years old with advanced dMMR/MSI-H gastric cancer; Neoadjuvant therapy is needed (immunotherapy, chemotherapy + immunotherapy); The patient voluntarily and agreed to join the clinical research.
Who cannot join
- Gastric cancer combined with invasion and metastasis; Gastric cancer combined with other malignant tumors; Gastric cancer combined with dysfunction of other organs; Unwilling to participate in clinical research.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Watching and Waiting in West China Hospital
Chengdu, Sichuan, 610041
About this study
Official title: Non-surgical Management After Neoadjuvant Immunotherapy for Locally Advanced dMMR/MSI-H Gastric Cancer: WWWGC Phase II Study
Gastric cancer is one of the most common cancers worldwide and has a poor prognosis Immunotherapy significantly improves the prognosis of gastric cancer. In resectable gastric/gastroesophageal junction adenocarcinoma (GAC/GEJA) C, mismatch repair deficiency (dMMR)/microsatellite instability (MSI-H) can improve survival, and immunotherapy can avoid chemotherapy or surgery. The dMMR/MSI-H status is the strongest predictive biomarker for the benefit of immunotherapy with anti-programmed death receptor 1 and its ligands (PD-1/PD-L1) in advanced solid tumors, especially metastatic gastric/gastroesophageal junction adenocarcinoma. The INFINITY study provides Durvalumab combined with Tremelimumab as a treatment option with significant benefits for preoperative treatment of dMMR/MSI GAC/GEJAC, as well as the feasibility of non-surgical treatment strategies for such gastric cancer patients At present, there are no studies related to Asian gastric cancer patients, which are worthy of further verification and exploration in Asian gastric cancer cohorts.
What is being measured
The primary outcome is the main question the study is designed to answer.
Recurrence-free survival (RFS)
The recurrence-free survival time of gastric cancer patients
Measured: One year, three years, or five years after the end of immunotherapy
Overall survival (OS)
The period from the start of randomization grouping in a clinical trial to the death of a patient for any cause
Measured: One year, three years, or five years after the end of immunotherapy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jun 2026
- Study start1 Jul 2026
- Primary completion30 Jun 2027 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non-surgical Management;dMMR/MSI-H Gastric Cancer;Neoadjuvant ImmunotherapyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Yong Zhou
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Yong Zhou, West China Hospital
- Investigators
- yong zhou, Professor, Study director, West China Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07646574
- Sponsor's protocol ID
- ChiCTR2600120174
- Status last verified
- May 2026
- First submitted
- 4 May 2026
- Last updated
- 19 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Non-surgical Management After Neoadjuvant Immunotherapy for Locally Advanced dMMR/MSI-H Gastric Cancer: WWWGC Phase II Study
- ClinicalTrials.gov ID
- NCT07646574
- Acronym / sponsor ID
- ChiCTR2600120174
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 12 participants (estimated)
- Lead sponsor
- Yong ZhouUniversity, hospital or other
- Study start
- 1 Jul 2026 (actual)
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 12 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Gastric cancer is one of the most common cancers worldwide and has a poor prognosis Immunotherapy significantly improves the prognosis of gastric cancer. In resectable gastric/gastroesophageal junction adenocarcinoma (GAC/GEJA) C, mismatch repair deficiency (dMMR)/microsatellite instability (MSI-H) can improve survival, and immunotherapy can avoid chemotherapy or surgery. The dMMR/MSI-H status is the strongest predictive biomarker for the benefit of immunotherapy with anti-programmed death receptor 1 and its ligands (PD-1/PD-L1) in advanced solid tumors, especially metastatic gastric/gastroesophageal junction adenocarcinoma. The INFINITY study provides Durvalumab combined with Tremelimumab as a treatment option with significant benefits for preoperative treatment of dMMR/MSI GAC/GEJAC, as well as the feasibility of non-surgical treatment strategies for such gastric cancer patients At present, there are no studies related to Asian gastric cancer patients, which are worthy of further verification and exploration in Asian gastric cancer cohorts.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patients over 18 years old with advanced dMMR/MSI-H gastric cancer
Key inclusion criteria (1 listed)
- Patients over 18 years old with advanced dMMR/MSI-H gastric cancer; Neoadjuvant therapy is needed (immunotherapy, chemotherapy + immunotherapy); The patient voluntarily and agreed to join the clinical research.
Key exclusion criteria (1 listed)
- Gastric cancer combined with invasion and metastasis; Gastric cancer combined with other malignant tumors; Gastric cancer combined with dysfunction of other organs; Unwilling to participate in clinical research.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Recurrence-free survival (RFS)
Time frame: One year, three years, or five years after the end of immunotherapy
The recurrence-free survival time of gastric cancer patients
Overall survival (OS)
Time frame: One year, three years, or five years after the end of immunotherapy
The period from the start of randomization grouping in a clinical trial to the death of a patient for any cause
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
yong zhou, Professor study director
West China Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Non-surgical Management;dMMR/MSI-H Gastric Cancer;Neoadjuvant Immunotherapy, run by Yong Zhou at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 19 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recurrence-free survival (RFS) (time frame: One year, three years, or five years after the end of immunotherapy). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2026; AzTrials last refreshed its copy on 6 Nov 2026.